智通财经APP获悉，Plus Therapeutics (PSTV.US)周四表示，其针对肺癌患者软脑膜转移的治疗药物Rhenium (186Re) Obisbemeda获得美国食品药品监督管理局 (FDA)孤儿药认定。受此提振，该公司股价周四收涨311.43%，盘后续涨超50%。

根据消息，市值210万美元的临床阶段制药公司Plus Therapeutics, Inc. (NASDAQ: PSTV )今日宣布，其研究性治疗药物Rhenium (186Re) Obisbemeda获得美国食品药品监督管理局（FDA）授予的孤儿药资格认证（ODD），用于治疗肺癌患者的脑膜转移（LM）。根据InvestingPro数据显示，该公司现金储备高于债务，但分析师预计今年仍将无法实现盈利。

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for ...

A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to ...

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

Ian Everard warns of a looming precious metals supply crunch. He highlights manipulated markets, dwindling silver stocks, and ...

Researchers have developed a drug shown to significantly extend survival time for patients with glioblastoma, the most common primary brain tumor in adults, according to results of a new trial.

AUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage ...

Plus Therapeutics (PSTV) announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D. The ...

A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to extend survival for patients with glioblastoma, the most common primary brain ...

Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung ...

Plus Therapeutics (PSTV) announces the publication of results in a peer-reviewed manuscript titled, “Treatment of Recurrent Glioma by Rhenium ...